On October 29, 2025, Bio-Rad Laboratories reported third-quarter earnings with sales of US$653 million and a net loss of US$341.9 million, while also completing a major share repurchase and announcing ...

Bio-Rad Laboratories BIO recently announced the launch of four new Droplet Digital PCR (ddPCR) platforms. The newly introduced instruments include the company's QX Continuum ddPCR system, along with ...

Bio-Rad Laboratories, Inc. (CA, USA) recently launched its ddPCR Microsatellite Instability (MSI) Assay, which detects instability in the genome that makes people susceptible to colorectal cancer and ...

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its ...

HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of four new Droplet ...

Bio-Rad Laboratories, Inc. today announced the launch of new PrimePCR Droplet Digital PCR (ddPCR™) Assays. This release expands Bio-Rad’s offering of predesigned validated copy number assays to a ...

Bio-Rad Laboratories, Inc. BIO announced that the performance of its QX200 Droplet Digital polymerase chain reaction (PCR) (ddPCR) System for the clinical detection of SARS-CoV-2 was proved to be more ...

Q3 2025 Management View Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the recent launch of the Vericheck ddPCR™ Replication ...